Teachers Retirement System of The State of Kentucky maintained its position in shares of Haemonetics Corporation (NYSE:HAE) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,700 shares of the medical instruments supplier’s stock at the close of the 2nd quarter. Teachers Retirement System of The State of Kentucky’s holdings in Haemonetics Corporation were worth $699,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Haemonetics Corporation by 48,854.9% in the 1st quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after purchasing an additional 6,276,880 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Haemonetics Corporation by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,743,044 shares of the medical instruments supplier’s stock worth $187,303,000 after purchasing an additional 48,719 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Haemonetics Corporation by 9.3% in the 2nd quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock worth $110,104,000 after purchasing an additional 238,294 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Haemonetics Corporation by 1.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,699,353 shares of the medical instruments supplier’s stock worth $68,943,000 after purchasing an additional 17,963 shares during the last quarter. Finally, State Street Corp lifted its holdings in Haemonetics Corporation by 8.3% in the 1st quarter. State Street Corp now owns 1,268,107 shares of the medical instruments supplier’s stock worth $51,449,000 after purchasing an additional 97,466 shares during the last quarter.

Several equities research analysts recently weighed in on HAE shares. Jefferies Group LLC restated a “buy” rating and issued a $48.00 target price on shares of Haemonetics Corporation in a report on Thursday, July 27th. Zacks Investment Research lowered Haemonetics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. BidaskClub lowered Haemonetics Corporation from a “hold” rating to a “sell” rating in a report on Friday, June 23rd. Finally, Barrington Research upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Haemonetics Corporation currently has an average rating of “Hold” and a consensus price target of $44.83.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/10/16/teachers-retirement-system-of-the-state-of-kentucky-holds-position-in-haemonetics-corporation-hae.html.

Haemonetics Corporation (NYSE:HAE) opened at 45.62 on Monday. The company has a market capitalization of $2.40 billion, a P/E ratio of 592.47 and a beta of 0.87. The firm has a 50-day moving average price of $43.70 and a 200 day moving average price of $41.64. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $46.85.

Haemonetics Corporation (NYSE:HAE) last released its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The company had revenue of $211.00 million during the quarter, compared to analysts’ expectations of $211.29 million. During the same period last year, the firm posted $0.25 earnings per share. The business’s revenue was up .5% on a year-over-year basis. Analysts expect that Haemonetics Corporation will post $1.61 EPS for the current year.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.